Baidu
map

Blood:血小板通过Clec-2与平足蛋白相互作用调节肺发育

2018-06-02 MedSci MedSci原创

中心点:血小板Clec-2与淋巴平足蛋白通过促进肥胖成纤维细胞分化协同调节肺发育。肺泡管成纤维细胞分化在一定程度上受血小板被Clec-2/平足蛋白相互作用激活释放TGF-β调节。摘要:血小板不仅仅参与血栓形成和止血,还参与其他的病理生理过程,包括肿瘤转移和炎症。但是,血小板在固体器官发育中是否发挥作用尚不明确。近日,Blood杂志上发表一篇文章,研究人员发现血小板可通过血小板激活受体(C型凝集素样

中心点:

血小板Clec-2与淋巴平足蛋白通过促进肥胖成纤维细胞分化协同调节肺发育。

肺泡管成纤维细胞分化在一定程度上受血小板被Clec-2/平足蛋白相互作用激活释放TGF-β调节。

摘要:

血小板不仅仅参与血栓形成和止血,还参与其他的病理生理过程,包括肿瘤转移和炎症。但是,血小板在固体器官发育中是否发挥作用尚不明确。近日,Blood杂志上发表一篇文章,研究人员发现血小板可通过血小板激活受体(C型凝集素样受体2[Clec-2;由Clec1b编码])及其配体(平足蛋白,一种膜蛋白)之间的相互作用调节肺发育。

敲除小鼠血小板的Clec-2可导致肺畸形,进而导致呼吸衰竭和新生鼠死亡。在这些胚胎中,初级肺泡隔中缺失α平滑肌动蛋白阳性的肺泡管成纤维细胞(adMYFs),导致缺乏肺泡弹性纤维和肺畸形。

本研究结果提示adMYFs缺乏是由非间皮细胞(luMCs),adMYFs的祖细胞,分化异常导致的。在发育的肺的肺泡上皮细胞(AECs)、luMCs和淋巴内皮细胞(LECs)上可检测到平足蛋白表达。LEC特异性敲除平足蛋白小鼠表现为新生鼠致死和Clec1b-/-样肺发育异常。除此之外,Clec1b-/-样肺异常还可在血小板减少症或TGF-β敲除的胎鼠中观察到。

综上所述,研究人员认为血小板上的Clec-2与LECs上的平足蛋白相互作用通过TGF-β信号刺激luMCs分化成adMYF,从而调节肺正常发育。

原始出处:

Nagaharu Tsukiji,et al.Platelets play an essential role in murine lung development through Clec-2/podoplanin interaction. Blood  2018  :blood-2017-12-823369;  doi: https://doi.org/10.1182/blood-2017-12-823369

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2005570, encodeId=c4d320055e0bb, content=<a href='/topic/show?id=ad7d482983' target=_blank style='color:#2F92EE;'>#CLEC-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4829, encryptionId=ad7d482983, topicName=CLEC-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jan 11 18:04:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909245, encodeId=d4d319092450d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Nov 30 21:04:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347303, encodeId=b715134e303d4, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471590, encodeId=4a9c14e15905e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321234, encodeId=df0532123481, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jun 03 23:06:54 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320936, encodeId=148f32093634, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jun 02 22:03:55 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2005570, encodeId=c4d320055e0bb, content=<a href='/topic/show?id=ad7d482983' target=_blank style='color:#2F92EE;'>#CLEC-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4829, encryptionId=ad7d482983, topicName=CLEC-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jan 11 18:04:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909245, encodeId=d4d319092450d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Nov 30 21:04:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347303, encodeId=b715134e303d4, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471590, encodeId=4a9c14e15905e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321234, encodeId=df0532123481, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jun 03 23:06:54 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320936, encodeId=148f32093634, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jun 02 22:03:55 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2005570, encodeId=c4d320055e0bb, content=<a href='/topic/show?id=ad7d482983' target=_blank style='color:#2F92EE;'>#CLEC-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4829, encryptionId=ad7d482983, topicName=CLEC-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jan 11 18:04:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909245, encodeId=d4d319092450d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Nov 30 21:04:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347303, encodeId=b715134e303d4, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471590, encodeId=4a9c14e15905e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321234, encodeId=df0532123481, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jun 03 23:06:54 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320936, encodeId=148f32093634, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jun 02 22:03:55 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
    2018-06-04 neurowu
  4. [GetPortalCommentsPageByObjectIdResponse(id=2005570, encodeId=c4d320055e0bb, content=<a href='/topic/show?id=ad7d482983' target=_blank style='color:#2F92EE;'>#CLEC-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4829, encryptionId=ad7d482983, topicName=CLEC-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jan 11 18:04:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909245, encodeId=d4d319092450d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Nov 30 21:04:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347303, encodeId=b715134e303d4, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471590, encodeId=4a9c14e15905e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321234, encodeId=df0532123481, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jun 03 23:06:54 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320936, encodeId=148f32093634, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jun 02 22:03:55 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
    2018-06-04 ylz8405
  5. [GetPortalCommentsPageByObjectIdResponse(id=2005570, encodeId=c4d320055e0bb, content=<a href='/topic/show?id=ad7d482983' target=_blank style='color:#2F92EE;'>#CLEC-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4829, encryptionId=ad7d482983, topicName=CLEC-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jan 11 18:04:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909245, encodeId=d4d319092450d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Nov 30 21:04:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347303, encodeId=b715134e303d4, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471590, encodeId=4a9c14e15905e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321234, encodeId=df0532123481, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jun 03 23:06:54 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320936, encodeId=148f32093634, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jun 02 22:03:55 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
    2018-06-03 1e1b8538m79(暂无匿称)

    不错的文章值得拥有哦

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2005570, encodeId=c4d320055e0bb, content=<a href='/topic/show?id=ad7d482983' target=_blank style='color:#2F92EE;'>#CLEC-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4829, encryptionId=ad7d482983, topicName=CLEC-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jan 11 18:04:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909245, encodeId=d4d319092450d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Nov 30 21:04:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347303, encodeId=b715134e303d4, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471590, encodeId=4a9c14e15905e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon Jun 04 12:04:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=321234, encodeId=df0532123481, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Sun Jun 03 23:06:54 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320936, encodeId=148f32093634, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jun 02 22:03:55 CST 2018, time=2018-06-02, status=1, ipAttribution=)]
    2018-06-02 惠映实验室

    学习了.谢谢分享.

    0

相关资讯

Blood:对血小板脂质进行综合性分析,鉴定对血小板活化至关重要的脂质

中心点:首次定量分析动态血小板脂质调节,揭示血小板活化的关键脂质变化。SMPD1可通过调节lyso-sphingomyelin调控血小板脂质和激活。摘要:血小板的完整性和功能显著依赖于脂质成分。但是,迄今为止,血小板的脂质含量仍无定量数据。对此,Bing Peng等人在一个定量的血脂平台上通过脂类特定性协议检测小鼠血小板的脂质。结果显示血小板脂质体包含近400种脂质种类,浓度范围覆盖7个数量级。对

IGLH:血小板阻抗测定法:一种测量血小板粘附和扩散的新技术

现如今,血栓形成对发病率和死亡率起着重要的作用。抗血栓药物是最常见的处方药之一。需要彻底了解血小板功能,才能获得最佳的临床护理。血小板粘附是血小板血栓形成过程的独立进程。尽管如此,目前还没有一种标准的方法可以用来来测量血小板粘附。阻抗测定是一种用于分析细胞粘附、增殖、存活和细胞毒性最可靠、最先进的技术。我们提出了一种可行的新方法,用于分离测量2个重要的血小板功能-----粘附和扩散。 研究人

Mol Ther:上海药物所发现整合素aIIbβ3的种属差异与单抗诱导的血小板减少症相关

在目前世界范围内,治疗性单克隆抗体(Monoclonal antibodies,mAbs)销售额已达数百亿美元,占到整个生物制药市场份额的三成以上。虽然大部分mAbs在人体中能够良好地耐受,但也依然会造成包括免疫反应、感染性疾病、自身免疫疾病、血小板减少、血栓形成障碍、皮炎及心血管毒性等毒副作用。因此,如何在药物研发前期尽早地发现mAbs造成的不良反应显得极为重要。

Blood:灭活血小板的病原体是否影响其止血效果?

中心点:仅在意向治疗分析中,病原体灭活性血小板的止血效果上为非劣效性。与动脉模型相比,应用病原体灭活性血小板时不能预防同种异体免疫。摘要:病原体失活的浓缩血小板可降低血源性感染的风险。但灭活病原体对血小板功能和输血的止血作用的影响尚不明确。近日Blood杂志上发表一篇相关文章,Pieter F. van der Meer等人进行一随机的非劣效性试验,对比用核黄素和紫外B光照技术病原体灭活血小板(干

EuroPCR 2018丨抗血小板界的“多面手”,你认识吗?

新研究丰富了替格瑞洛的多效性:替格瑞洛除抗血小板作用之外,还可带来额外获益。

Blood:GPIbα对血小板介导的肝TPO合成至关重要!

中心点:血小板GPIbα可诱导肝促血小板生成素(TPO)合成、维持TPO血液浓度。抗胞外GPIbα抗体可减少TPO合成,在免疫介导的血小板减少症中影响TPO水平。摘要:促血小板生成素(TPO),一种主要由肝脏合成的造血生长因子,对血栓形成至关重要。当前主流理论认为循环TPO水平是通过被血小板和巨核细胞的表面c-Mpl受体内化作用清除来维持的。近期,Miao Xu等人意外的发现与野生型(WT)小鼠相

Baidu
map
Baidu
map
Baidu
map